Fosamax Osteonecrosis of the Jaw Settlement: Statute of Limitations for Fosamax in California

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specific Exposure Concerns

For decades, general health and science information has served as the foundation for public understanding of medication safety and long-term treatment outcomes. Within this legacy framework, patients and healthcare providers have relied on broad educational resources to navigate the benefits and risks associated with prescription therapies. As the domain of mass production expands, the focus necessarily shifts from generalized awareness to specific, population-level exposure patterns. In the context of bisphosphonate therapies such as Fosamax, the transition from general health guidance to occupational and patient exposure concerns becomes critical. The widespread manufacturing and distribution of these medications mean that large cohorts of individuals—both patients and those involved in production—may encounter sustained contact with the active compound. This exposure, particularly over extended periods, raises questions about cumulative risk that extend beyond the original therapeutic indications. The legal landscape, including the statute of limitations for Fosamax-related claims in California, reflects this evolving understanding.

Bridging to Fosamax and Osteonecrosis of the Jaw

Here, the bridge from general health information to occupational exposure concern is built on the recognition that mass production environments can amplify exposure scenarios, necessitating a more targeted evaluation of risk factors that were not fully anticipated in earlier, broader health communications. Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use is associated with a known adverse effect: osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw presents as exposed bone in the oral cavity that persists for more than eight weeks without evidence of healing. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Symptoms may include pain, swelling, paresthesia, suppuration, and loosening of teeth. Diagnosis is primarily clinical, supported by imaging such as panoramic radiographs or CT scans that may reveal sequestra, sclerotic bone, or periosteal reaction. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, though a subset may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Fosamax Pharmacology and Mechanistic Pathways

Fosamax is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. Its high affinity for hydroxyapatite leads to prolonged retention in bone, particularly at sites of high turnover such as the jaw. The mechanistic pathways linking Fosamax to ONJ involve suppression of bone remodeling, which impairs the ability of the jawbone to repair microdamage and respond to local infections or trauma. Bisphosphonates also inhibit angiogenesis and may alter immune function, contributing to avascular necrosis. The risk of ONJ increases with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Multiscale characterization of jawbone tissue has provided insights into how bone-related complications, including bisphosphonate-related ONJ, develop in the context of postmenopausal osteoporosis (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Risk Factors and Adequacy of Warnings

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the adequacy of these warnings has been a subject of legal scrutiny. Some plaintiffs have argued that the warnings did not sufficiently emphasize the risk of ONJ, particularly for patients without cancer who were using Fosamax for osteoporosis. The label does state that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as jaw pain were similar in the Fosamax and placebo groups, which may have contributed to delayed recognition of the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Settlement-Related Considerations for Affected Patients in California

For patients in California who have developed ONJ after using Fosamax, legal claims may be subject to a statute of limitations. In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. Given that the time to onset of ONJ symptoms can vary from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), and that the condition may be associated with dental procedures, the timeline between exposure and documented harm is critical. Patients should document the date of first Fosamax use, the date of ONJ diagnosis, and any dental procedures or infections that preceded the condition. Settlement considerations may include the severity of ONJ, the need for surgical intervention, and the impact on quality of life. The risk of ONJ may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), so patients who used Fosamax for several years may have stronger claims. It is important for affected individuals to consult with a legal professional to understand the specific deadlines and requirements for filing a claim in California.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in California?

In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For Fosamax-associated ONJ, the timeline between exposure and diagnosis is critical, and patients should document the date of first use and diagnosis.

What are the known risk factors for developing osteonecrosis of the jaw from Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cgi?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.